Last reviewed 2026-04-22 · How we verify

KeraStat® Gel application

The Metis Foundation · FDA-approved active Small molecule

KeraStat® Gel application is a Topical wound healing agent Small molecule drug developed by The Metis Foundation. It is currently FDA-approved for Chronic wounds, Acute wounds, Diabetic foot ulcers.

KeraStat® Gel is a topical hydrogel formulation designed to promote wound healing and tissue regeneration by maintaining a moist wound environment and delivering keratinocyte growth factors.

KeraStat® Gel is a topical hydrogel formulation designed to promote wound healing and tissue regeneration by maintaining a moist wound environment and delivering keratinocyte growth factors. Used for Chronic wounds, Acute wounds, Diabetic foot ulcers.

At a glance

Generic name	KeraStat® Gel application
Sponsor	The Metis Foundation
Drug class	Topical wound healing agent
Modality	Small molecule
Therapeutic area	Dermatology / Wound Care
Phase	FDA-approved

Mechanism of action

The gel creates an optimal microenvironment for wound healing by maintaining moisture and potentially delivering growth factors that stimulate keratinocyte proliferation and migration. This promotes re-epithelialization and tissue repair in chronic or acute wounds. The hydrogel formulation allows for sustained release of bioactive components while protecting the wound bed.

Approved indications

Chronic wounds
Acute wounds
Diabetic foot ulcers

Common side effects

Local irritation or erythema
Allergic contact dermatitis

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KeraStat® Gel application CI brief — competitive landscape report
KeraStat® Gel application updates RSS · CI watch RSS
The Metis Foundation portfolio CI

Frequently asked questions about KeraStat® Gel application

What is KeraStat® Gel application?

KeraStat® Gel application is a Topical wound healing agent drug developed by The Metis Foundation, indicated for Chronic wounds, Acute wounds, Diabetic foot ulcers.

How does KeraStat® Gel application work?

KeraStat® Gel is a topical hydrogel formulation designed to promote wound healing and tissue regeneration by maintaining a moist wound environment and delivering keratinocyte growth factors.

What is KeraStat® Gel application used for?

KeraStat® Gel application is indicated for Chronic wounds, Acute wounds, Diabetic foot ulcers.

Who makes KeraStat® Gel application?

KeraStat® Gel application is developed and marketed by The Metis Foundation (see full The Metis Foundation pipeline at /company/the-metis-foundation).

What drug class is KeraStat® Gel application in?

KeraStat® Gel application belongs to the Topical wound healing agent class. See all Topical wound healing agent drugs at /class/topical-wound-healing-agent.

What development phase is KeraStat® Gel application in?

KeraStat® Gel application is FDA-approved (marketed).

What are the side effects of KeraStat® Gel application?

Common side effects of KeraStat® Gel application include Local irritation or erythema, Allergic contact dermatitis.

Drug class: All Topical wound healing agent drugs
Manufacturer: The Metis Foundation — full pipeline
Therapeutic area: All drugs in Dermatology / Wound Care
Indication: Drugs for Chronic wounds
Indication: Drugs for Acute wounds
Indication: Drugs for Diabetic foot ulcers

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing